Deeptope specializes in high-throughput antibody characterization and optimization, providing precise epitope and paratope mapping solutions to enhance antibody candidates' developability. This technology enables rapid identification of binding sites and improves the efficiency of therapeutic antibody development.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody characterization and optimization methods are often time-consuming and lack the throughput needed to efficiently identify and improve antibody candidates for therapeutic development. Inefficient mapping of epitopes and paratopes can hinder the development of antibodies with optimal binding and developability properties.
Solution
Deeptope offers high-throughput antibody characterization and optimization services, focusing on precise epitope and paratope mapping to enhance the developability of antibody candidates. Their technology enables rapid identification of antibody binding sites, significantly improving the efficiency of therapeutic antibody development. By combining high-throughput methods, Deeptope accelerates the characterization of both antibody paratopes and epitopes, as well as the optimization of lead candidates. This approach reduces lead times and facilitates the selection of antibodies with improved developability profiles.
Target Audience
Deeptope's primary customers are pharmaceutical and biotechnology companies involved in therapeutic antibody discovery and development.
Features
- High-throughput epitope mapping for rapid identification of antibody binding sites on target antigens.
- High-throughput paratope mapping to characterize the antibody's binding region.
- Antibody lead optimization services to improve developability properties.
- Short lead times for all characterization and optimization steps.